Tracers / [64Cu]Pep-1L
[64Cu]Pep-1L
Also written as [Cu-64]Pep-1L
- Radionuclide
- Cu-64 t½ 762 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- NOTA-conjugated peptide (IL13RA2-targeted peptide, Pep-1L)
- Target / mechanism
- IL13RA2 (interleukin 13 receptor alpha 2) targeted peptide PMID 28562337
- Clinical application
- —
- Theranostic pair
- <a href="/tracers/ac225-pep1l/">ac225-pep1l</a>
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | — | — | >98% | NOTA-Pep-1L CPC Scientific, San Jose, CA | 28562337 2017 Oncotarget Both the peptides, Pep-1L and scrambled peptide-NOTA were radiolabeled with Cu-64 according to the previously reported methods |
Need this precursor?We can point you to suppliers for [64Cu]Pep-1L, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 28562337. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 28562337: 'NOTA-Pep-1L'.